Hormone-Sensitive Advanced Prostate Cancer Treatment Market is Likely to Witness Steady Growth by 2033Posted by Ganesh Shinde on June 14th, 2023  The global Hormone-Sensitive Advanced Prostate Cancer Treatment Market is expected to be worth US$ 12.44 billion by 2023. According to Future Market Insights, the market will grow at a 7.2% CAGR through 2033, with a market value of US$ 24.94 billion. The key providers' principal mission is to translate science into revolutionary oncology medications for assisting patients with cancer around the world, where they pledge to potentially bringing new hope driving the purpose and enabling accessibility through their cancer treatments. The market for prostate cancer medications is being held back by recurrent/non-responsive prostate cancer. This is because recurrent/non-responsive prostate cancer cells cause cancer to recur or spread after first treatment. According to the American Society of Clinical Oncology (ASCO), 50% to 95% of men with high-risk prostate cancer in the United States experience recurrence after localised treatment. The prostate cancer medications market in the United States is regulated by the FDA, which is in charge of drug approval and establishing regulations for prostate cancer treatment. This was the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more are planned in the future. As a result, the regulatory environment around prostate cancer medications will attract additional drug producers to enter the market. Major Players
Get More Details@ https://www.futuremarketinsights.com/reports/hormone-sensitive-advanced-prostate-cancer-market Key Segments Profiled in the Hormone Sensitive Advanced Prostate Cancer Treatment Market Report By Treatment:
By End User:
Like it? Share it! More by this author |